Diagnosis and management of Guillian Barre Syndrome in children and adolescents

- References

1- Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36:123-133.

2- Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barre syndrome. Lancet.2016;388:717-727.

3- Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol. 1990;27(S1):S21-S24.

4-  F.G. Van der Meche, P.A. van Doorn, J. Meulstee, F.G. Jennekens, Diagnostic and classification criteria for the Guillain-Barre syndrome, Eur. Neurol. 45 (3)(2001) 133e139.

5- B.R. Wakerley, A. Uncini, N. Yuki, Guillain-Barre and Miller Fisher syndromes–new diagnostic classification, Nat. Rev. Neurol. 10 (9) (2014) 537e544.

6-  Richard A.C. Hughes, A.V. Swan, van Doorn, A. Pieter, Intravenous immunoglobulin for Guillain-Barre syndrome, Cochrane Database Syst. Rev. (9) (2014), CD002063.

7- S. Chevret, R.A. Hughes, D. Annane, Plasma exchange for Guillain-Barre syndrome,

Cochrane Database Syst. Rev. 2 (2017), CD001798.

8-  R. Korinthenberg, J.S. M€onting, Natural history and treatment effects in Guillain-Barr_e syndrome: a multicentre study, Arch. Dis. Child. 74 (4) (1996) 281e287.

9- Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria. Brain. 2014;137:33-43.

10-  J. Roodbol, Y. de Wit, Marie-Claire, Bianca van den Berg, et al., Diagnosis of Guillain-Barre syndrome in children and validation of the Brighton criteria, J. Neurol. 264 (5) (2017) 856e861.

11-  Kahlmann V, Roodbol J, van Leeuwen N, et al. Validated age-specific reference values for CSF total protein levels in children. Eur J Pae- diatr Neurol. 2017;21:654-660.

12-  G.T. Doctor, S.K. Alexander, A. Radunovic, Guillain-Barre syndrome with exaggerated pleocytosis and anti-GM1 ganglioside antibodies, BMJ Case Rep. 2018 (2018).

13-  Richard A.C. Hughes, D.R. Cornblath, Guillain-Barre syndrome, Lancet 366 (9497) (2005) 1653e1666.

14-   Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299.

15-   Scottish Intercollegiate Guidelines Network (SIGN).

16-  Diagnosis and treatment of Guillain-Barre Syndrome in childhood and adolescence: An evidence- and consensus-based guideline, 2020

17-  European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome, 2023

18-  J.J. Sejvar, K.S. Kohl, J. Gidudu, et al., Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data, Vaccine 29 (3) (2011) 599e612.

19-  A. Uncini, S. Kuwabara, Electrodiagnostic criteria for Guillain-Barre syndrome:a critical revision and the need for an update, Clin. Neurophysiol. 123 (8)(2012) 1487e1495.

20-   Van den Bergh, Y.K. Peter, F. Pi_eret, J.L. Woodard, et al., Guillain-Barr_e Syndrome Subtype Diagnosis: A Prospective Multicentric European Study, Muscle Nerve, 2018.

21-  Umapathi T, Lim CSJ, Ng BCJ, Goh EJH, Ohnmar O. A simplified, graded, electrodiagnostic criterion for Guillain-Barre syndrome that incorporates sensory nerve conduction studies. Sci Rep. 2019;9:7724

22-  Derksen A, Ritter C, Athar P, et al. Sural sparing pattern discriminates Guillain-Barre syndrome from its mimics. Muscle Nerve. 2014; 50:780-784.

23-  Coskun A, Kumandas S, Pac A, Karahan OI, Gulec M, Baykara M. Childhood Guillain-Barre syndrome. MR imaging in diagnosis and follow-up. Acta Radiol. 2003;44:230-235.

24-   Gorson KC, Ropper AH, Muriello MA, Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barre syndrome. Neurology. 1996;47:813-817.

 

25-    Mulkey SB, Glasier CM, El-Nabbout B, et al. Nerve root enhancement on spinal MRI in pediatric Guillain-Barre syndrome. Pediatr Neurol. 2010;43:263-269.

26-  Yikilmaz A, Doganay S, Gumus H, Per H, Kumandas S, Coskun A. Magnetic resonance imaging of childhood Guillain-Barre syndrome. Childs Nerv Syst. 2010;26:1103-1108.

27-  Jacobs, B. C. et al. The spectrum of antecedent infections in Guillain- Barré syndrome: a case- control study. Neurology 51, 1110–1115 (1998)

28-  Cao- Lormeau, V. M. et al. Guillain- Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case- control study. Lancet 387, 1531–1539 (2016).

29-  Van den Berg, B. et al. Guillain- Barré syndrome associated with preceding hepatitis E virus infection. Neurology 82, 491–497 (2014).

30-  Patone M, Handunnetthi L, Saatci D, et al. Neurological complications after first dose of COVID- 19 vaccines and SARS- CoV- 2 infection. Nat Med. 2021;27:2144-2153.

31-  Keddie S, Pakpoor J, Mousele C, et al. Epidemiological and cohort study finds no association between COVID- 19 and Guillain- Barre syndrome. Brain. 2021;144:682-693.

32-  Martin Arias LH, Sanz R, Sainz M, Treceno C, Carvajal A. Guillain- Barre syndrome and influenza vaccines: a meta- analysis. Vaccine. 2015;33:3773-3778.

33-   N. Andrews, J. Stowe, R. Al-Shahi Salman, E. Miller, Guillain-Barre syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series, Vaccine 29 (45) (2011) 7878e7882.

34-  P. Haber, J. Sejvar, Y. Mikaeloff, F. DeStefano, Vaccines and guillain-barre syndrome, Drug Saf. 32 (4) (2009) 309e323.

35-  Hashemilar M, Barzegar M, Nikanfar M, et al. Evaluating the status of antiganglioside antibodies in children with Guillain-Barre syndrome. Neuroimmunomodulation. 2014;21:64-68.

36-  Gregson NA, Koblar S, Hughes RA. Antibodies to gangliosides in Guillain-Barre syndrome: specificity and relationship to clinical features. Q J Med. 1993;86:111-117.

37-  Caudie C, Quittard Pinon A, Taravel D, et al. Preceding infections and anti-ganglioside antibody profiles assessed by a dot immunoassay in 306 French Guillain-Barre syndrome patients. J Neurol. 2011; 258:1958-1964.

38-  Carpo M, Pedotti R, Lolli F, et al. Clinical correlate and fine specificity of anti-GQ1b antibodies in peripheral neuropathy. J Neurol Sci.1998;155:186-191.

 

39-   Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serumanti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: clinical and immunohistochemical studies. Neurology. 1993;43:1911-1917.

40-  R. Korinthenberg, J. Schessel, J. Kirschner, J.S. Monting, Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barre syndrome: a randomized trial, Pediatrics 116 (1) (2005) 8-14.

41-  D. Singh-Grewal, A. Kemp, M. Wong, A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions, Arch Dis Child. 91 (8) (2006) 651 – 654.

42-  Verboon, C. ∙ van Doorn ∙ Pieter, A.Treatment dilemmas in Guillain-Barre syndrome.J. Neurol. Neurosurg. Psychiatry. 2017; 88:346-352

43-   S. Chevret, R.A. Hughes, D. Annane, Plasma exchange for Guillain-Barre syndrome, Cochrane Database Syst. Rev. 2 (2017), CD001798.

44-  Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978;2:750-753.

45-  RA Hughes, RAC, Cornblath DR. Guillain-Barre syndrome. Lancet 2005;366 (9497): 1653-66.

46-  Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2016;10: CD001446.

47-   Guillain-Barre Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barre syndrome. Lancet 1993;341:586-590.

48-   van Koningsveld R, Schmitz PI, Meche FG, Visser LH, Meulstee J,Van Doorn PA. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet. 2004;363:192-196.

49-  Kleyweg RP, van der Meche FG. Treatment related fluctuations in Guillain-Barre syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry. 1991;54:957-960.

50-  Hughes RA, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain. 2007;130:2245-2257.

51-  Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-second revision.J Peripher Nerv Syst. 2021;26:242-268.

52-  Ruts L, Drenthen J, Jacobs BC, van Doorn PA. Distinguishing acute onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010;74:1680-1686

53-  Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain. 2008;131:1197-1208.

54-  Davidson AI, Halstead SK, Goodfellow JA, et al. Inhibition of complement in Guillain-Barre syndrome: the ICA-GBS study. J Peripher Nerv Syst. 2017;22:4-12.

55-   Misawa S, Kuwabara S, Sato Y, et al. Safety and efficacy of eculizumab in Guillain-Barre syndrome: a multicentre, double-blind, randomized phase 2 trial. Lancet Neurol. 2018;17:519-529.

56-  van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barre syndrome. Lancet Neurol. 2007;6:589-594.

57-  Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, Jacobs BC. Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology. 2011;76:968-975.

58-  Alessandro L, Pastor Rueda JM, Wilken M, et al. Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients. J Peripher Nerv Syst. 2018;23:154-158.

59-   Dionne A, Nicolle MW, Hahn AF. Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve. 2010;41:202-207. 

60-  Grimm A, Oertl H, Auffenberg E, et al. Differentiation between Guillain-Barre syndrome and acute-onset chronic inflammatory demyelinating polyradiculoneuritis: a prospective follow-up study using ultrasound and neurophysiological measurements. Neurotherapeutics. 2019;16:838-847.

61-  Vural A, Doppler K, Meinl E. Autoantibodies against the node of Ranvier in seropositive chronic inflammatory demyelinating polyneuropathy: diagnostic, pathogenic, and therapeutic relevance. Front Immunol. 2018;9:1029.

62-  Y. Nevo, H. Topaloglu, 88th ENMC international workshop: childhood chronic inflammatory demyelinating polyneuropathy (including revised diagnostic criteria), Naarden, The Netherlands, December 8-10, Neuromuscul. Disord. 12(2) (2000) 195e200, 2002.